Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

Probiodrug (Group)

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. *

 

Period Start 1997-06-01 established
Products Industry drug development technology
  Industry 2 QC inhibitor (glutam(in)yl cyclase inhibitor)
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)
     
Region Region Halle (Saale)
  Country Germany
  Street 22 Weinbergweg
  City 06120 Halle (Saale)
  Tel +49-345-55599-00
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2016-12-31)
  Currency EUR
  Annual sales 44,000 (operating income (2015) 2015-12-31)
  Profit -13,891,000 (2016-12-31)
  Cash 9,300,000 (2018-03-31)
     
    * Document for �About Section�: Probiodrug AG. (10/7/15). "Press Release: Probiodrug Signs Agreement with Rentschler for Manufacture of Its pGlu-Abeta Targeting Antibody PBD-C06". Halle/Saale & Laupheim.
     
   
Record changed: 2018-10-07

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Probiodrug (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px




» top